Regencell Bioscience Holdings Ltd is a biotechnology company focused on developing innovative therapies for neurological disorders. The company is actively engaged in the research and commercialization of novel treatments aimed at addressing conditions such as attention deficit hyperactivity disorder (ADHD) and other cognitive impairments. Through its cutting-edge approaches and commitment to scientific advancement, Regencell strives to enhance the quality of life for individuals affected by these challenges, with a strong emphasis on evidence-based solutions and therapeutic efficacy.